U.S. markets closed

Nurix Therapeutics, Inc. (NRIX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
18.50-0.76 (-3.95%)
At close: 04:00PM EDT
19.42 +0.92 (+4.97%)
After hours: 07:10PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Head and Shoulders Bottom

Head and Shoulders Bottom

Previous Close19.26
Bid18.45 x 900
Ask18.49 x 800
Day's Range17.93 - 18.83
52 Week Range7.52 - 37.42
Avg. Volume596,229
Market Cap870.275M
Beta (5Y Monthly)1.90
PE Ratio (TTM)N/A
EPS (TTM)-3.05
Earnings DateOct 12, 2022 - Oct 17, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for NRIX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Nurix Therapeutics, Inc.
    ITOS: Rating decreased to a HOLDITEOS THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $22.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • GlobeNewswire

    Nurix Therapeutics Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer

    SAN FRANCISCO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Eric Schlezinger, J.D. has joined the company as chief people officer. Mr. Schlezinger is an industry veteran with extensive experience leading and developing human resources at high-growth private and public biopharma companies. “Eric is a proven leader in building and maintaining exceptional compa

  • Insider Monkey

    Cathie Wood’s 10 Favorite Stock Picks for the Rest of 2022

    In this article, we discuss Cathie Wood’s 10 favorite stock picks for the rest of 2022. If you want to see more stocks in this selection, click Cathie Wood’s 5 Favorite Stock Picks for the Rest of 2022. Cathie Wood, the chief of ARK Investment Management, has been making headlines recently as her hedge fund […]

  • GlobeNewswire

    Nurix Therapeutics Announces $40 Million Registered Direct Offering

    SAN FRANCISCO, July 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it has entered into a securities purchase agreement with two healthcare-focused investment funds to sell, in a registered direct offering, pre-funded warrants to purchase 2,869,440 shares of common stock at a price of $13.939 per pre-funded warrant for total gross proceeds of approximately $40 milli